MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges-Reference-Cited by-同舟云学术

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Published:2020-02-20 Issue:4 Volume:107 Page:762-772
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Krishnaswami Sriram¹,Austin Daren²,Della Pasqua Oscar³,Gastonguay Marc R.⁴,Gobburu Jogarao⁵,Graaf Piet H.⁶,Ouellet Daniele⁷,Tannenbaum Stacey⁸,Visser Sandra A. G.⁹

Affiliation:

1. Pfizer Groton Connecticut USA

2. GSK London UK

3. University College London London UK

4. Metrum Research Group Tariffville Connecticut USA

5. University of Maryland College Park Maryland USA

6. Certara Canterbury UK

7. Pfizer Collegeville Pennsylvania USA

8. Astellas Northbrook Illinois USA

9. GSK Collegeville Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1788

Reference18 articles.

1. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

2. Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs

3. Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

4. Implementation of Quantitative and Systems Pharmacology in Large Pharma

5. Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate–Severe Asthma;Advances in Therapy;2024-06-25

2. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers;European Journal of Pharmaceutics and Biopharmaceutics;2024-06

3. Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program;Clinical Pharmacology & Therapeutics;2024-03-22

4. An industry perspective on current QSP trends in drug development;Journal of Pharmacokinetics and Pharmacodynamics;2024-03-05

5. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma;CPT: Pharmacometrics & Systems Pharmacology;2023-08-02